Antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1(PD-1), and programmed death-ligand 1 (PD-L1), all of which increase the immune response against the tumor by blocking immune-regulating proteins that downregulate the immune system, have increased response rates and OS in melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, urothelial carcinoma, and squamous cell carcinoma of the head and neck [49–55]. This evidence concerns the gene CD274 and neoplasm.